MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/105/0.2/21.03.25 | Market Closed - Bid/Ask 11:38:57 26/06/2024 pm IST | After market 12:07:15 am | |||
| 8.51 EUR | -5.34% |
|
8.54 | +0.35% |
| Current month | +30.48% | ||
| 1 month | +28.06% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 26/24/26 | 8.51 | -5.34% |
| 25/24/25 | 8.99 | +11.40% |
| 24/24/24 | 8.07 | -0.98% |
| 21/24/21 | 8.15 | -2.86% |
| 20/24/20 | 8.39 | +4.48% |
Delayed Quote Börse Stuttgart
Last update June 26, 2024 at 11:38 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MB5MAB |
| ISIN | DE000MB5MAB4 |
| Date issued | 14/04/2023 |
| Strike | 105 $ |
| Maturity | 21/03/2025 (268 Days) |
| Parity | 5 : 1 |
| Emission price | 1.29 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.18 € |
|---|---|
| Lowest since issue | 0.96 € |
| Spread | 0.02 € |
| Spread % | 0.23% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,028
DKK
Average target price
938.1
DKK
Spread / Average Target
-8.74%
- Stock Market
- Warrants
- Warrant
